Gerard A. Blaufarb

The American Intellectual Property Law Association (AIPLA) is a professional organization that provides education, advocacy, and networking opportunities for intellectual property (IP) law practitioners. The organization is based in Arlington, VA and offers a variety of resources for its members, including access to committees focused on specific areas of IP law, continuing legal education (CLE) courses, and publications such as the quarterly journal and Innovate magazine. AIPLA also advocates for policies that support the protection of IP rights and provides resources for students and the public.

American Bar Association provides legal services. It provides law school accreditation, continuing legal education, legal information and other services to assist legal professionals. The firm has members which include judges, court administrators, law professors, and non-practicing attorneys. The company was founded on August 21, 1878 and is headquartered in Chicago, IL.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

US Patent & Trademark Office provides patent and trade marks services. It advises the president of the United States, the secretary of commerce, and U.S. government agencies on intellectual property (IP) policy, protection, and enforcement; and promotes IP protection. The company is headquartered in Alexandria, VA.

Encore Pharmaceuticals, Inc. (EPI) is a drug discovery and development company with advanced proprietary products for the treatment and prevention of cancer and neurologic and cardiovascular diseases. EPI's principal drug innovations have come from discoveries made by researchers at Loma Linda University Medical Center (LLUMC). EPI was founded in 1997 and concluded a technology transfer license agreement with LLUMC in January 1999. The discovery operation continues to be located in the LLUMC environment where operations in 1999 were expanded to include clinical development of EPI's lead drug candidate E-7869 (now known as MPC-7869) for treatment of prostate and colon cancer. The company's research efforts have also led to the discovery of a -tocopherol (member of the Vitamin E family) metabolite designated as E-8110 (also known as LLU- ) and bioanalogs which have natriuretic (sodium excretion) activity. These compounds are being examined for their anti-hypertensive, anti-oxidant and anti-cancer properties. Patent applications for EPI drug discoveries have been filed and are in review worldwide